Six new medicines leap towards EU approval
The recommendations include new treatments for cancer and intraocular pressure and prevention of uncomplicated flu.
Read More
Tag: Gamifant
Sobi to refile Gamifant following CHMP rejection
The company’s peak sales forecast of more than $500 million remains unchanged
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
